Elevance Health, Inc. $ELV Holdings Raised by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. grew its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 2.3% in the 4th quarter, HoldingsChannel reports. The firm owned 85,171 shares of the company’s stock after acquiring an additional 1,898 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Elevance Health were worth $29,857,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ELV. Physician Wealth Advisors Inc. lifted its holdings in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares during the last quarter. Rossby Financial LCC lifted its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares in the last quarter. ORG Partners LLC lifted its stake in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Elevance Health in the 4th quarter worth about $38,000. Finally, Dorato Capital Management purchased a new stake in Elevance Health in the 4th quarter worth about $41,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Stock Up 2.4%

ELV opened at $402.69 on Tuesday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $408.00. The business has a 50-day moving average of $345.97 and a 200-day moving average of $339.77. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market capitalization of $87.45 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 2.22 and a beta of 0.66.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same period last year, the business earned $11.97 EPS. The business’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts forecast that Elevance Health, Inc. will post 26.94 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio is currently 29.26%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ELV shares. Truist Financial increased their price objective on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $405.00 to $435.00 in a research note on Wednesday, April 29th. UBS Group increased their price objective on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Robert W. Baird increased their price objective on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Finally, Guggenheim increased their price objective on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $407.05.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.